Effects of a 4-week course of recombinant human erythropoietin (rHuEpo) therapy on four circulating endothelium-derived cardiovascular risk markers were studied in 20 patients receiving maintenance hemodialysis in relation to surrogates of chronic inflammation, liver function, and arterial blood pressure. Soluble intercellular adhesion molecule-1 (sICAM-1), antigens of plasminogen activator inhibitor-i (PAI-i:Ag) and von Willebrand factor (vWF:Ag), and soluble thrombomodulin (sTM) were determined by immunoenzymatic assays. C-reactive protein; (xi acid-glycoprotein; ax-antitrypsin; immunoglobulin M, A, and G; interleukin-6; lipoprotein(a); fibrinogen; total protein; albumin; total cholesterol; hepatitis B and C markers; liver enzymes; prothrombin time; and phosphorus were measured by routine methods. The rHuEpo treatment resulted in a 25% increase in sICAM-1 (Wilcoxon's p = 0.001), a 50% increase in PAI-i:Ag (p = 0.004), a 15% increase in sTM (p = 0.002), and did not change vWF:Ag levels. The increase in sICAM-1 concentration directly correlated with that of PAI-i:Ag (Spearman's rho = 0.483, p = 0.031). The rHuEpo-induced increases in hemoglobin, platelets, and pre-dialysis diastolic blood pressure levels did not correlate with the increments in the endothelial markers studied. In conclusion, short-term rHuEpo therapy activates vascular endothelium in patients receiving maintenance hemodialysis. This specific effect may influence cardiovascular risk.
1. Gris J-C, Branger B, Vecina F, et al. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int1994;46:807-807.
2.
2. Takagi M, Wada H, Mukai K, et al. Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance haemodialysis. Blood Coag Fibrinol1994;4:713-713.
3.
3. Stenvinkel P. Lindholm B, Heimburger M, et al. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: associations with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant2000;15:1624-1624.
4.
4. Borawski J, Naumnik B, Pawlak K, et al. Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response. Nephrol Dial Transplant2001;16;1442-1442.
5.
5. Borawski J, Pawlak K, Mysliwiec M. Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients. Nephron (in press).
6.
6. Huraib S, Al-Momen AK, Gader AMA, et al. Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients. Clin Nephrol1991;36:252-252.
7.
7. Zwaginga JJ, Ijsseldijk MJW, de Groot PG, et al. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma. Thromb Haemost1991;66:638-638.
8.
8. Ozsoylu S, Gursel T. von Willebrand factor and rise in ristocetin co-factor with erythropoietin. Lancet1993; 341:1221-1221.
9.
9. Taylor JE, Belch JJF, McLaren M, et al. Effect of nifedipine on changes in fibrinogen and von Willebrand factor in haemodialysis patients treated with recombinant human erythropoietin. Blood Coag Fibrinol1995;6:100-100.
10.
10. Moia M, Vizzotto L, Cattaneo M, et al. Improvement in the hemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet1987;28:1227-1227.
11.
11. Gordge MP, Leaker B, Patel A, et al. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation. Thromb Res1990;57:171-171.
12.
12. Johnson WJ, McCarthy JT, Yanagihara T, et al. Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagulability. Kidney Int1990;38:919-919.
13.
13. Christensson AG, Danielson BG, Lethagen SR. Normalization of haemoglobin concentration with recombinant erythropoietin has minimal effect on blood hemostasis. Nephrol Dial Transplant2001;16:313-313.
14.
14. Malyszko JS, Malyszko J, Pawlak K, et al. Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin. Nephron2000;84:305-305.
15.
15. Borawski J, Naumnik B, Pawlak K, et al. Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients. Nephrol Dial Transplant2001;16:787-787.
16.
16. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood1998;91:3527-3527.
17.
17. Mantovani A, Sozzani S, Vecchi A, et al. Cytokine activation of endothelial cells: New molecules for an old paradigm. Thromb Haemost1997;78 [suppl 11]:406-406.
18.
18. Blann AD. Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual term?Blood Coag Fibrinol2000;11:623-623.
19.
19. Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. The ECAT study group. Circulation1996;94:2057-2057.
20.
20. Folsom AR, Wu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) study. Circulation1997;96:1102-1102.
21.
21. Hwang S-J, Ballantyne CM, Sharett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. The Atherosclerosis Risk in Communities (ARIC) study. Circulation1997;96:4219-4219.
22.
22. Salomaa V, Matei C, Aleksic N, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) study: A case cohort study. Lancet1999;353:1729-1729.
23.
23. Pannier B, Guerin AP, Marchais SJ, et al. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int2000;57:1091-1091.
24.
24. Allegra A, Buemi M, Corica F, et al. Erythropoietin administration induces an increase of serum levels of soluble E-selectin and soluble intercellular adhesion molecule 1. Nephron1999;82:361-361.
25.
25. Nagai T, Akizawa T, Kohjiro S, et al. rHuEPO enhances the production of plasminogen activator inhibitor-i in cultured endothelial cells. Kidney Int1996;50:102-102.
26.
26. Aunsholt NA, Ahlbom G, Steffensen G, et al. Fibrinolytic capacity in hemodialysis patients treated with recombinant human erythropoietin. Nephron1992;62:284-284.
27.
27. Malyszko J, Malyszko JS, Borawski J, et al. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res1995;77:33-33.
28.
28. Aguilera A, Selgas R, Ruiz-Caravaca ML, et al. Effects of recombinant human erythropoietin on functional and injury endothelial markers in peritoneal dialysis patients. Perit Dial Int1999;19 [suppl 2]:161-161.
29.
29. Kuriyama S, Hopp L, Yoshida H, et al. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Am J Hypertens1996; 9:426-426.
30.
30. Mannucci PM. Von Willebrand factor. A marker of endothelial damage?Arterioscler Thromb Vasc Biol1998; 18:1359-1359.
31.
31. Iseki K, Nishime K, Uehara H, et al. Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron1996;72:30-30.
32.
32. Carlini RG, Obialo CI, Rothstein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens1993;6:103-103.
33.
33. Takahashi K, Totsune K, Imai Y, et al. Plasma concentrations of immunoreactive endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sci1993;80:47-47.
34.
34. Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA1990;87:5978-5978.
35.
35. Bode-Boger SM, Boger RH, Kuhn M, et al. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int1996;500:1255-1255.
36.
36. Carlini RG, Dusso A, Obialo CI, et al. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int1993;43:1010-1010.
